Canaccord Genuity Maintains Buy on Travere Therapeutics, Lowers Price Target to $35
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Edward Nash maintains a 'Buy' rating on Travere Therapeutics (NASDAQ:TVTX) but lowers the price target from $37 to $35.
July 18, 2023 | 1:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Despite the lowered price target, Canaccord Genuity maintains a 'Buy' rating on Travere Therapeutics, indicating continued confidence in the company's prospects.
The lowered price target might initially seem negative, but the maintained 'Buy' rating indicates that the analyst still sees potential in the company. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100